Advertisement

Docetaxel

  • Ines Mader
  • Patrizia E. Fürst-Weger
  • Robert M. Mader
  • Elisabeth I. Semenitz
  • Robert Terkola
  • Sabine M. Wassertheurer

Keywords

Drug Invest Sodium Cromoglycate Clin Drug Invest Skin Model Disposable Syringe 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Original articles

  1. [1]
    Bertelli G, Cafferata MA, Ardizzoni A, et al: Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer 79: 2266–2268, 1997.PubMedCrossRefGoogle Scholar
  2. [2]
    Goodman M, Stewart I, Lydon J, et al: Use caution when managing paclitaxel and taxotere infiltrations. Oncol Nurs Forum 23: 541–542, 1996.PubMedGoogle Scholar
  3. [3]
    Panday VR, Huizing MT, Huinink WW, et al: Hypersensitivity reactions to the taxanes paclitaxel and docetaxel. Clin Drug Invest 14: 418–427, 1997.CrossRefGoogle Scholar

Secondary literature

  1. [4]
    van Gemmern R: Gewebstoxizität und Paravasatbehandlung neuer Zytostatika. Krankenhauspharmazie 17: 471–473, 1996.Google Scholar
  2. [5]
    Rhone-Poulenc Rorer, personal communication, August 1998.Google Scholar
  3. [6]
    Dorr RT: Author reply to Bertelli G et al: Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer 79: 2268–2269, 1997.CrossRefGoogle Scholar
  4. [7]
    Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.Google Scholar
  5. [8]
    Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.Google Scholar
  6. [9]
    Berdel WE, Schmoll HJ, Michele T, et al: Prävention und Therapie von Paravasaten/Extravasaten. In: Schmoll HJ, Höffken K, Possinger K (eds) Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie. Springer, Vol 1, 3rd edition: 1689–1701, 1999.Google Scholar
  7. [10]
    Bokemeyer C: Dermatoxizität antineoplastischer Substanzen. In: Schmoll HJ, Höffken K, Possinger K (eds) Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie. Springer, Vol 1, 3rd edition: 14111426, 1999.Google Scholar
  8. [11]
    Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: A42–44, 1997.Google Scholar
  9. [12]
    Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.Google Scholar
  10. [13]
    Summary of product characteristics Taxotere® (Austria), Rhone-Poulenc Rorer, February 1998.Google Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Ines Mader
    • 1
  • Patrizia E. Fürst-Weger
    • 2
  • Robert M. Mader
    • 3
  • Elisabeth I. Semenitz
    • 4
  • Robert Terkola
    • 5
  • Sabine M. Wassertheurer
    • 6
  1. 1.Austrian Breast and Colorectal Cancer Study GroupViennaAustria
  2. 2.SMZ FloridsdorfKrankenhaus und GeriatriezentrumViennaAustria
  3. 3.Clinical Division of Oncology, Department of Medicine IUniversity HospitalViennaAustria
  4. 4.AnstaltsapothekeLandeskrankenhaus — Universitätskliniken InnsbruckAustria
  5. 5.Kaiser-Franz-Josef HospitalViennaAustria
  6. 6.Apotheke LKH-Univ.-Klinikum GrazAustria

Personalised recommendations